Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company focused on B-cell diseases, with news flow centered on its CD20-targeted monoclonal antibody BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). This news page aggregates company announcements, clinical data updates, financial results, and corporate presentations related to TGTX stock.
Recent press releases highlight preliminary and reported revenue from BRIUMVI, including disclosures that product revenue consists primarily of net product sales of BRIUMVI in the United States and sales to ex-U.S. partners. Investors can follow updates on revenue guidance, operating expense targets, and commentary on how BRIUMVI commercialization influences overall company performance.
TG Therapeutics also issues frequent news about its development programs. These items include progress in the ENHANCE Phase 3b trial evaluating a simplified intravenous dosing schedule for BRIUMVI, the Phase 3 pivotal program for subcutaneous ublituximab, and the Phase 1 trial of azer-cel, an allogeneic CD19 CAR T therapy in autoimmune disease. Additional releases cover long-term ULTIMATE I & II trial data, real-world ENABLE observational study outcomes, and schedules of data presentations at neurology and multiple sclerosis congresses.
Corporate news includes participation in major healthcare and biotechnology investor conferences, rankings such as the Deloitte Technology Fast 500, and announcements of share repurchase authorizations. By following this TGTX news feed, readers can monitor how clinical results, regulatory milestones, commercialization updates, and financial disclosures intersect for TG Therapeutics and its lead therapy BRIUMVI.
TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Phoenix, Arizona from May 28-31, 2025. The presentations include three key studies:
1. A platform presentation on the relationship between serum immunoglobulin levels and infections during long-term ublituximab treatment by Dr. Bruce Cree
2. A poster on infusion tolerability from the ENAMOR real-world observational survey presented by Dr. Edward Fox
3. A poster updating safety and tolerability data of 30-minute ublituximab infusions from the ENHANCE study by Dr. John Foley
All presentations are scheduled for May 29, 2025, and the data will be made available on TG Therapeutics' website after the presentations.
TG Therapeutics has scheduled a conference call for Monday, May 5, 2025, at 8:30 AM ET to discuss their first quarter 2025 financial results and provide a business outlook for the remainder of the year. The call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer.
Participants can join the call using the following dial-in numbers:
- U.S.: 1-877-407-8029
- International: 1-201-689-8029
A live webcast will be available on the Events page in the Investors & Media section of www.tgtherapeutics.com. An audio recording will remain accessible for 30 days after the call on the company website. Financial results will be released via press release before the conference call.
TG Therapeutics (NASDAQ: TGTX) presented data for BRIUMVI® (ublituximab-xiiy) in treating relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting. The ENHANCE trial demonstrated that a single 600 mg dose of BRIUMVI on Day 1 was well-tolerated, leading the company to consider a registration-directed trial to combine the currently approved Day 1 and Day 15 doses into a single administration.
Two key presentations were featured:
- Efficacy and Safety of Modified Ublituximab Regimen (ENHANCE) by Dr. John Foley
- Five-year Ublituximab results in Relapsing Multiple Sclerosis from ULTIMATE I and II Studies' open-label extension by Dr. Bruce Cree
TG Therapeutics (NASDAQ: TGTX) presented three significant data sets for BRIUMVI® (ublituximab-xiiy) in treating relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting.
Key findings include:
- The ENAMOR survey, covering ~400 patients across 21 MS centers, showed improved tolerability and lower infusion-related reactions compared to Phase 3 trials
- 90% of surveyed patients received acetaminophen pre-medication, potentially explaining the better tolerance rates
- The company announced ENABLE, a new Phase 4 96-week observational study, which will track approximately 500 patients across 100 US MS centers
- Five-year BRIUMVI treatment data showed consistent serious infection rates with Phase 3 trials and no Progressive Multifocal Leukoencephalopathy (PML) cases
TG Therapeutics (NASDAQ: TGTX) has announced the publication of two significant journal articles focusing on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis (MS) treatment. The first publication in Frontiers in Immunology presents a case series of seven MS patients who switched to BRIUMVI from other anti-CD20 therapies due to efficacy or tolerability issues.
The second article, published in CNS DRUGS, examines the evolution of anti-CD20 treatments for MS, discussing key characteristics such as scaffold, mechanism of action, and Fc engineering that may influence therapeutic efficacy and patient experience.
Michael S. Weiss, Executive Chairman and CEO, emphasized these publications provide rationale for switching patients within the CD20 class before abandoning it entirely. The company continues to study this phenomenon through their ongoing ENHANCE and ENABLE studies to further validate these initial findings.
TG Therapeutics (NASDAQ: TGTX) has announced upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data for relapsing multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting in San Diego (April 5-9, 2025).
The presentations include five poster sessions focusing on:
- Long-term ublituximab treatment's impact on immunoglobulin levels and serious infections
- Real-world infusion tolerability (ENAMOR survey)
- ENABLE Phase 4 observational study
- Five-year results from ULTIMATE I and II studies' open-label extension
- Modified ublituximab regimen (ENHANCE) efficacy and safety
Key researchers presenting include Dr. Bruce Cree from UC San Francisco's Weill Institute for Neurosciences, Dr. Ed Fox from TG Therapeutics, and Dr. John Foley from Rocky Mountain Multiple Sclerosis.
TG Therapeutics (NASDAQ: TGTX) reported strong financial results for Q4 and full year 2024, with BRIUMVI U.S. net revenue reaching $103.6 million in Q4 and $310 million for the full year, marking approximately 250% growth year-over-year.
Key highlights include:
- Target guidance of $540 million in total global revenue for 2025
- Extended BRIUMVI patent protection through 2042
- Successful European launch with partner Neuraxpharm
- Impressive 5-year clinical data showing 92% of patients free from disability progression
The company reported net income of $23.3 million for Q4 2024 and $23.4 million for the full year. Cash position stands at $311.0 million as of December 31, 2024. R&D expenses increased to $94.3 million for 2024, while SG&A expenses rose to $154.3 million, primarily due to BRIUMVI commercialization efforts.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
